Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time course of pharmacodynamic response, safety and pharmacokinetics of bimekizumab in moderate to severe chronic plaque psoriasis
2016-002368-15Phase 2Terminated
- Sponsor
- UCB
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoint: Change from Baseline in PASI at Week 28. Started Aug 2016; status: terminated.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2016-002368-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002368-15.